Literature DB >> 15728504

The staphylococcal superantigen-like protein 7 binds IgA and complement C5 and inhibits IgA-Fc alpha RI binding and serum killing of bacteria.

Ries Langley1, Bruce Wines, Natasha Willoughby, Indira Basu, Thomas Proft, John D Fraser.   

Abstract

The staphylococcal superantigen-like proteins (SSLs) are close relatives of the superantigens but are coded for by a separate gene cluster within a 19-kb region of the pathogenicity island SaPIn2. rSSL7 (formally known as SET1) bound with high affinity (K(D), 1.1 nM) to the monomeric form of human IgA1 and IgA2 plus serum IgA from primate, pig, rat, and horse. SSL7 also bound the secretory form of IgA found in milk from human, cow, and sheep, and inhibited IgA binding to cell surface FcalphaRI (CD89) and to a soluble form of the FcalphaRI protein. In addition to IgA, SSL7 bound complement factor C5 from human (K(D), 18 nM), primate, sheep, pig, and rabbit serum, and inhibited complement-mediated hemolysis and serum killing of a Gram-negative organism Escherichia coli. SSL7 is a superantigen-like protein secreted from Staphylococcus aureus that blocks IgA-FcR interactions and inhibits complement, leading to increased survival of a sensitive bacterium in blood.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15728504     DOI: 10.4049/jimmunol.174.5.2926

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  74 in total

1.  Staphylococcal superantigen-like protein 3 binds to the Toll-like receptor 2 extracellular domain and inhibits cytokine production induced by Staphylococcus aureus, cell wall component, or lipopeptides in murine macrophages.

Authors:  Ryosuke Yokoyama; Saotomo Itoh; Go Kamoshida; Takemasa Takii; Satoshi Fujii; Tsutomu Tsuji; Kikuo Onozaki
Journal:  Infect Immun       Date:  2012-06-04       Impact factor: 3.441

Review 2.  Exploring Staphylococcus aureus pathways to disease for vaccine development.

Authors:  Andrea DeDent; Hwan Keun Kim; Dominique Missiakas; Olaf Schneewind
Journal:  Semin Immunopathol       Date:  2011-12-01       Impact factor: 9.623

Review 3.  Metal ion acquisition in Staphylococcus aureus: overcoming nutritional immunity.

Authors:  James E Cassat; Eric P Skaar
Journal:  Semin Immunopathol       Date:  2011-11-03       Impact factor: 9.623

4.  Molecular mechanisms of complement evasion: learning from staphylococci and meningococci.

Authors:  Davide Serruto; Rino Rappuoli; Maria Scarselli; Piet Gros; Jos A G van Strijp
Journal:  Nat Rev Microbiol       Date:  2010-06       Impact factor: 60.633

5.  Substrate recognition by complement convertases revealed in the C5-cobra venom factor complex.

Authors:  Nick S Laursen; Kasper R Andersen; Ingke Braren; Edzard Spillner; Lars Sottrup-Jensen; Gregers R Andersen
Journal:  EMBO J       Date:  2011-01-07       Impact factor: 11.598

Review 6.  Recombinant IgA production for mucosal passive immunization, advancing beyond the hurdles.

Authors:  Vikram Virdi; Paloma Juarez; Veronique Boudolf; Ann Depicker
Journal:  Cell Mol Life Sci       Date:  2015-10-28       Impact factor: 9.261

7.  Crystal structure of staphylococcal enterotoxin I (SEI) in complex with a human major histocompatibility complex class II molecule.

Authors:  Marisa M Fernández; Rongjin Guan; Chittoor P Swaminathan; Emilio L Malchiodi; Roy A Mariuzza
Journal:  J Biol Chem       Date:  2006-07-06       Impact factor: 5.157

Review 8.  Complement evasion by human pathogens.

Authors:  John D Lambris; Daniel Ricklin; Brian V Geisbrecht
Journal:  Nat Rev Microbiol       Date:  2008-02       Impact factor: 60.633

9.  Human milk secretory immunoglobulin a and lactoferrin N-glycans are altered in women with gestational diabetes mellitus.

Authors:  Jennifer T Smilowitz; Sarah M Totten; Jincui Huang; Dmitry Grapov; Holiday A Durham; Carol J Lammi-Keefe; Carlito Lebrilla; J Bruce German
Journal:  J Nutr       Date:  2013-09-18       Impact factor: 4.798

Review 10.  Anaphylatoxins: their role in bacterial infection and inflammation.

Authors:  Pieter-Jan Haas; Jos van Strijp
Journal:  Immunol Res       Date:  2007       Impact factor: 2.829

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.